A Phase 1, Open-Label Study, to Evaluate the Safety and Tolerability of a Single Inhalation of SM04646 Solution in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs SM 04646 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors Samumed
- 17 Jul 2017 According to a Samumed media release, detailed analysis, including safety and pK results, will be presented at future medical conferences.
- 17 Jul 2017 Status changed from recruiting to completed, as reported by a Samumed media release.
- 25 Jun 2016 New trial record